Y Intercept Hong Kong Ltd grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 322.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 56,522 shares of the biotechnology company’s stock after purchasing an additional 43,129 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Exelixis were worth $1,882,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the company. Seizert Capital Partners LLC grew its holdings in shares of Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock worth $12,195,000 after buying an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp purchased a new position in shares of Exelixis during the third quarter worth about $4,396,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares during the last quarter. Finally, CWA Asset Management Group LLC purchased a new position in shares of Exelixis during the third quarter worth about $577,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on EXEL. BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $36.00 to $40.00 in a report on Friday, December 20th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target on the stock. in a report on Monday. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price objective on shares of Exelixis in a research report on Wednesday, October 30th. Finally, Guggenheim restated a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $37.24.
Exelixis Trading Down 0.6 %
EXEL stock opened at $36.92 on Wednesday. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $37.59. The company has a market cap of $10.33 billion, a price-to-earnings ratio of 20.86, a PEG ratio of 1.13 and a beta of 0.53. The firm has a 50 day moving average of $34.26 and a 200-day moving average of $31.46.
Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Sell-side analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.85% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
See Also
- Five stocks we like better than Exelixis
- Using the MarketBeat Dividend Tax Calculator
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- 3 Tickers Leading a Meme Stock Revival
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to trade using analyst ratings
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.